JB111
Alzheimer's disease associated with PPT1 haploinsufficiency
Pre-clinicalActive
Key Facts
Indication
Alzheimer's disease associated with PPT1 haploinsufficiency
Phase
Pre-clinical
Status
Active
Company
About Jaya Biosciences
Jaya Biosciences is a preclinical biotech focused on a novel approach to neurodegenerative diseases by targeting specific genetic drivers, particularly lysosomal dysfunction. Its lead candidate, JB111, is an AAV9-mediated gene therapy designed to address PPT1 haploinsufficiency in Alzheimer's disease, representing a precision medicine strategy for a subset of patients. The company is building a strong intellectual property portfolio with recent patent grants in key global markets. Backed by a team with deep experience in lysosomal biology and gene therapy, Jaya is positioning itself in the high-need but challenging field of CNS gene therapy.
View full company profile